Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells $228,333.60 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $76.67 on Friday. The firm’s fifty day simple moving average is $65.94 and its 200-day simple moving average is $61.85. The stock has a market capitalization of $10.80 billion, a price-to-earnings ratio of -35.66 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $82.26. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The business had revenue of $73.74 million for the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company’s quarterly revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.75 EPS. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Royal Bank Of Canada boosted their price objective on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. B. Riley Financial boosted their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $78.00 to $100.00 in a research note on Tuesday, April 21st. Sanford C. Bernstein boosted their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They issued an “overweight” rating and a $88.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.80.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $25,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $32,000. WPG Advisers LLC boosted its position in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 431 shares in the last quarter. Hantz Financial Services Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 471 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $54,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and $100 price target on Arrowhead Pharmaceuticals, while also lifting its FY2026 earnings estimate, reinforcing a bullish long-term view on the company’s RNAi pipeline.
• Positive Sentiment: Other recent analyst actions remain constructive, including Royal Bank of Canada raising its price target to $87, JPMorgan starting coverage with an Overweight rating, and Sanford C. Bernstein boosting its target to $46.
• Neutral Sentiment: Arrowhead presented at the Bank of America Global Healthcare Conference, but the headline does not indicate a major new clinical or financial update that would materially change near-term expectations. Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: HC Wainwright made only small mixed tweaks to its 2026-2027 EPS forecasts, suggesting the analyst still sees the bigger story as intact despite minor quarter-to-quarter changes.
• Negative Sentiment: Director Hongbo Lu sold 2,970 shares in a pre-arranged 10b5-1 transaction. The sale was modest relative to his remaining stake, but insider selling can still be viewed cautiously by investors.
• Negative Sentiment: Arrowhead’s latest quarterly results showed a large year-over-year revenue decline and continued losses, reminding investors that the company remains unprofitable and dependent on future pipeline progress.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.